Michael Bringuier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael Bringuier has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Elena Paillaud
Univ Paris Est Creteil, INSERM, IMRB, Creteil, France
6 shared publications - Etienne Brain
Department of Medical Oncology, Institut Curie, Saint-Cloud, France
6 shared publications - Florence Canoui-Poitrine
Service de Santé Publique, GHU AP-HP Hôpitaux Universitaires Henri-Mondor, Créteil; UMR U955 - UPEC/Inserm U955, Faculté de Médecine de Créteil, Créteil, France; Département Masters, Faculté de Santé - UPEC, Créteil, France
6 shared publications - Capucine Baldini
Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Université Paris-Saclay, 94805 Villejuif, France
5 shared publications - Philippe Caillet
Henri Mondor's Hospital, Creteil, France
5 shared publications - Christos Chouaid
Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Elsevier in The Breast
- Vol. 89
Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
- 30 July 2026
- Published by Elsevier in The Breast
- Vol. 89
Open AccessReal-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
- Top Cited PapersOpen Access
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer
- Open Access
- 5 December 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116166
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
- 5 December 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116166
Open AccessRecent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
- 3 January 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Reliability of the cumulative illness rating scale for geriatrics for assessing multimorbidity in older patients with cancer: results from the ELCAPA cohort
Comorbidities are common in older patients with cancer. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G, developed in 1992) provides a comprehensive assessment of comorbidities and is independently associated with the mortality rate, the hospital admission rate and functional limitations. Although the literature data indicate that the CIRS-G’s reliability is good to very good, most of the studies were small and did not include cancer patients. Here, we evaluated the CIRS-G’s reliability in a large, prospective cohort of cancer patients aged 70 or over. A stratified, random sample of 150 patients was used to assess inter-rater reliability, and a random sample of 30 patients was evaluated by two investigators to assess intra-rater reliability. For inter-rater reliability, the observed intraclass correlation coefficient (ICC) [95% confidence interval] of 0.53 [0.12–0.74] was substantially lower than the literature values. For intra-rater reliability, the ICC was 0.66 [0.40–0.82] for investigator 1 and 0.77 [0.54–0.89) for investigator 2. These findings suggest that applying the CIRS-G consistently across raters and centres may be challenging in real-world oncology settings for older patients with cancer. Revising the scoring guidelines could help improve its reliability.
- 3 January 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Reliability of the cumulative illness rating scale for geriatrics for assessing multimorbidity in older patients with cancer: results from the ELCAPA cohort
Comorbidities are common in older patients with cancer. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G, developed in 1992) provides a comprehensive assessment of comorbidities and is independently associated with the mortality rate, the hospital admission rate and functional limitations. Although the literature data indicate that the CIRS-G’s reliability is good to very good, most of the studies were small and did not include cancer patients. Here, we evaluated the CIRS-G’s reliability in a large, prospective cohort of cancer patients aged 70 or over. A stratified, random sample of 150 patients was used to assess inter-rater reliability, and a random sample of 30 patients was evaluated by two investigators to assess intra-rater reliability. For inter-rater reliability, the observed intraclass correlation coefficient (ICC) [95% confidence interval] of 0.53 [0.12–0.74] was substantially lower than the literature values. For intra-rater reliability, the ICC was 0.66 [0.40–0.82] for investigator 1 and 0.77 [0.54–0.89) for investigator 2. These findings suggest that applying the CIRS-G consistently across raters and centres may be challenging in real-world oncology settings for older patients with cancer. Revising the scoring guidelines could help improve its reliability.
- Open Access
- 1 February 2024
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 53 (2)
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach
Background: Few studies of the under-representation of older adults in cancer clinical trials (CTs) have encompassed the entire pathway from a trial being available in a cancer centre to the patient’s invitation to participate and then agreement or refusal to participate. Objectives: The study’s primary objective was to evaluate CT non-invitation and refusal rates. The secondary objectives were to identify factors associated with non-invitation and refusal and to assess experiences of CT participation from the patients’ and professionals’ perspectives. Methods: Here, we used mixed methods and a socio-epidemiological approach to analyse reasons for the non-participation of eligible older patients with a solid cancer in cancer CTs in France. Results: We found that non-invitation and low CT participation are mainly related to the patients’ sociodemographic characteristics and living conditions (such as social isolation, being single, divorced or widowed, not having children and the absence of close family members) and the healthcare professionals’ perceptions of insufficient informal support or a high homecare requirement. Conclusion: Our results suggest that efforts to increase fair inclusion and the participation of older adults in CTs should target the physician–patient relationship, the medical profession and hospital funding, rather than the patient alone.
- 1 February 2024
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 53 (2)
Open AccessDisentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach
Background: Few studies of the under-representation of older adults in cancer clinical trials (CTs) have encompassed the entire pathway from a trial being available in a cancer centre to the patient’s invitation to participate and then agreement or refusal to participate. Objectives: The study’s primary objective was to evaluate CT non-invitation and refusal rates. The secondary objectives were to identify factors associated with non-invitation and refusal and to assess experiences of CT participation from the patients’ and professionals’ perspectives. Methods: Here, we used mixed methods and a socio-epidemiological approach to analyse reasons for the non-participation of eligible older patients with a solid cancer in cancer CTs in France. Results: We found that non-invitation and low CT participation are mainly related to the patients’ sociodemographic characteristics and living conditions (such as social isolation, being single, divorced or widowed, not having children and the absence of close family members) and the healthcare professionals’ perceptions of insufficient informal support or a high homecare requirement. Conclusion: Our results suggest that efforts to increase fair inclusion and the participation of older adults in CTs should target the physician–patient relationship, the medical profession and hospital funding, rather than the patient alone.
- 24 November 2023
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 193, 104212
Antibody drug conjugates in older patients: State of the art
- 24 November 2023
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 193, 104212
Antibody drug conjugates in older patients: State of the art
- 5 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (8) , S39
Predicting moderate and severe chemotherapy toxicity in older patients with cancer
- 5 November 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (8) , S39
Predicting moderate and severe chemotherapy toxicity in older patients with cancer
- Open Access
Prevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort Study
Older cancer patients have an elevated risk of sarcopenia. The aim was to estimate the prevalence of four criteria for sarcopenia case finding, assessment, diagnosis, and severity determination: abnormal strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F), low hand-grip strength (HGS), low arm circumference (AC, a muscle mass proxy), and low physical performance (PP). Sarcopenia (low HGS and AC) and severe sarcopenia (low HGS, AC, and PP) and their predictive values for 6-month mortality were estimated in the whole population and by metastatic status. We analyzed data from the NutriAgeCancer French nationwide study of cancer patients aged ≥70 referred for geriatric assessment before anti-cancer treatment. We performed Cox proportional hazards analysis for each criterion separately and all criteria combined. Overall, 781 patients from 41 geriatric oncology clinics were included (mean age: 83.1; females: 53%; main cancer types: digestive (29%) and breast (17%); metastases: 42%). The prevalence of abnormal SARC-F, low HGS, a low AC, low PP, sarcopenia, and severe sarcopenia were, respectively, 35.5%, 44.6%, 44.7%, 35.2%, 24.5%, and 11.7%. An abnormal SARC-F and/or low HGS, sarcopenia, and severe sarcopenia were associated with 6-month mortality in patients with metastases (adjusted hazard ratios [95% confidence interval]: 2.72 [1.34–5.49], 3.16 [1.48–6.75] and 6.41 [2.5–16.5], respectively). Sarcopenia was strongly predictive of 6-month mortality in patients with metastatic cancer.
Open AccessPrevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort Study
Older cancer patients have an elevated risk of sarcopenia. The aim was to estimate the prevalence of four criteria for sarcopenia case finding, assessment, diagnosis, and severity determination: abnormal strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F), low hand-grip strength (HGS), low arm circumference (AC, a muscle mass proxy), and low physical performance (PP). Sarcopenia (low HGS and AC) and severe sarcopenia (low HGS, AC, and PP) and their predictive values for 6-month mortality were estimated in the whole population and by metastatic status. We analyzed data from the NutriAgeCancer French nationwide study of cancer patients aged ≥70 referred for geriatric assessment before anti-cancer treatment. We performed Cox proportional hazards analysis for each criterion separately and all criteria combined. Overall, 781 patients from 41 geriatric oncology clinics were included (mean age: 83.1; females: 53%; main cancer types: digestive (29%) and breast (17%); metastases: 42%). The prevalence of abnormal SARC-F, low HGS, a low AC, low PP, sarcopenia, and severe sarcopenia were, respectively, 35.5%, 44.6%, 44.7%, 35.2%, 24.5%, and 11.7%. An abnormal SARC-F and/or low HGS, sarcopenia, and severe sarcopenia were associated with 6-month mortality in patients with metastases (adjusted hazard ratios [95% confidence interval]: 2.72 [1.34–5.49], 3.16 [1.48–6.75] and 6.41 [2.5–16.5], respectively). Sarcopenia was strongly predictive of 6-month mortality in patients with metastatic cancer.
- 17 January 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (2) , 101423
Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort
- 17 January 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (2) , 101423
Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort
- 28 June 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 172, 158-170
Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review
- 28 June 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 172, 158-170
Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review